The Safety and Tolerability of Candesartan Cilexetil in CHF

Braunwald E. Heart Failure (Chapter 233) in: Harrison's Principles of Internal Medicine 4th Edition 1998. Editors: Fauci AS et al., New York. 1287–98.

Senni M , Tribouilloy CM , Rodeheffer RJ. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282–9.

Ho KKL , Pinsky JL , Kannel WB , Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993; 22 Suppl A: 6A–13A.

Dickstein K , Chang P , Willenhelmer R. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. Am J Cardiol 1995; 26: 438–45.

CPMP/WWP/235/95, Revision 1: Note for guidance on clinical investigation of medicinal products for the treatment of cardiac failure. Adopted by CPMP December 1999.

McKelvie RS , Yusuf S , Pericak D. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) Pilot Study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056–64.

Pitt B , Segal R , Martinez FA. , on behalf of the ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52.

Pitt B , Poole-Wilson PA , Segal R. , on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.

Riegger GA , Bouzo H , Petr P. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 1999; 100: 2224–30.

Takeda , 1999. Study of the 3-month haemodynamic effects of 2 mg, 4 mg, and 16 mg candesartan cilexetil (TCV-116) in patients with impaired left ventricular function (heart failure - NYHA class II/III). A double-blind, randomised, placebo-controlled, multi-centre study.

Thompson SG , Pocock SJ. Can meta-analyses be trusted? Lancet 1991; 338: 1127–1130.

Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Department of Health and Human Services: Guideline for the format and content of the clinical and statistical sections of new drug applications. July 1988.